A 15-year follow-up study on the outcome in patients with early rheumatoid arthritis

REFERENCES

• Pincus T, Callahan LF, How many types of patients meet classification criteria for RA? (Editorial), J Rheumatol 21, 1385–1389 (1994).
   PubMed Web of Science ®Google Scholar
• Van der Heijde DM, van Leeuwen MA, van Riel PL et al., Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis, Arthritis Rheum 35, 26–35 (1992).
   PubMed Web of Science ®Google Scholar
• Van der Heide A, Jacobs JWG, Bijisma JWJ et al., The effectiveness of early treatment with ‘second line’ antirheumatic drugs. A randomized controlled trial, Ann Intern Med V2A, 699–707 (1996).
   Google Scholar
• Borg G, Allander E, Berg E et al., Auranofin treatment in early rheumatoid arthritis may postpone early retirement; results from a 2-year double blind trial, J Rheumatol 18, 1015–1020 (1991).
   PubMed Web of Science ®Google Scholar
• Hannonen P, Mottonen T, Hakola M, Oka M, Sulfasalazine in early rheumatoid arthritis; a 48-week, double-blind, prospective, placebo-controlled study, Arthritis Rheum 36, 1501–1509 (1993).
   Google Scholar
• Iannuzzi L, Dawson N, Zein N, Kushner I, Does drug therapy slow radiographic deterioration in rheumatoid arthritis? N Eng J Med 309, 1023–1028 (1983).
   PubMed Web of Science ®Google Scholar
• Nordstrom DM, West SG, Anderson PA, Sharp GT, Pulse methotrexate therapy in rheumatoid arthritis; a controlled prospective roentgenographic study, Ann Intern Med 107, 797–801 (1987).
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Polisson R, Blotner SD et al., The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36 week randomized trial comparing methotrexate and auranofin, Arthritis Rheum 36, 613–619 (1993).
   PubMed Web of Science ®Google Scholar
• Kushner I, Does aggressive therapy of rheumatoid arthritis affect outcome? (Editorial), J Rheumatol 16, 1–4(1989).
   PubMed Web of Science ®Google Scholar
• Drug Evaluation Committee of the Japan Rheumatism Foundation, Long term comparative studies on gold, D-penicillamine and NSAIDs for treatment of early rheumatoid arthritis; 1. Evaluation of one year’s treatment, Jpn J Rheumatol 1, 305–317 (1989).
   Google Scholar
• Lansbury J, Methods for evaluating rheumatoid arthritis, in: Arthritis and Allied Conditions, Hollander JC (Ed.), 7th edn, pp. 269–291. Lea and Febiger, Philadelphia (1969).
   Google Scholar
• Meenan RF, Mason JH, Anderson JJ et al., AIMS2. The content and properties of a revised and expanded arthritis impact measurement scales health status questionnaire, Arthritis Rheum 35, 1–10(1992).
   PubMed Web of Science ®Google Scholar
• Koote K, Isomaki H, Muturu O, Death rate and causes of death in RA patients during a period of five years, Scand J Rheumatol 6, 241–244 (1977).
   Google Scholar
• Van den Broucke J, Hazevoet HM, Cats A, Survival and cause of death in rheumatoid arthritis: a 25-year prospective follow up, J Rheumatol 11, 158–161 (1984).
   Google Scholar
• Yoshizawa Y, Kudo H, Iwano K et al., Causes of death in patients with rheumatoid arthritis — analysis of 117 cases for 13 years, Ryumachi 30, 247–254 (1990) (in Japanese).
   Google Scholar
• Steinbrocker O, Traeger CH, Batterman RC, Therapeutic criteria in rheumatoid arthritis, J Am Med Ass 160, 659–662 (1949).
   Google Scholar
• Makisara P, Nissila M, Kajander A et al., Comparison of penicillamine and gold treatment in early rheumatoid arthritis, Scand J Rheumatol 7, 166–170 (1978).
   PubMedGoogle Scholar
• Pincus T, Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials, J Clin Epidemiol 41, 1037–1041 (1988).
   PubMed Web of Science ®Google Scholar
• Wolfe F, Hawley DJ, Remission in rheumatoid arthritis, J Rheumatol 12, 245–252 (1985).
   PubMed Web of Science ®Google Scholar
• Mottonen T, Paimela L, Ahonen J et ai, Outcome in patients with early rheumatoid arthritis treated according to the ‘sawtooth’ strategy, Arthritis Rheum 39, 996–1005 (1996).
   PubMedGoogle Scholar
• Wolfe F, Hawley DJ, Cathey MA, Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts, J Rheumatol 15, 994–1002(1988).
   Google Scholar
• Fries JF, Reevaluating the therapeutic approach to rheumatoid arthritis; the ‘sawtooth’ strategy, J Rheumatol 17, 12–15 (1990).
   Google Scholar
• Rau R, Herborn G, Karger T, Werder D, Retardation of radiographic progression in rheumatoid arthritis with methotrexate therapy: a controlled study, Arthritis Rheum 34, 1236–1244 (1991).
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Nakata S, Takubo N, Can DMARDs prevent articular destruction in RA? J Orthopaed Rheum 9, 52–56 (1996).
   Google Scholar
• Egmose C, Lund B, Borg G et al, Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study, J Rheumatol 2, 2208–2213 (1995).
   Google Scholar
• Van der Heijde DM, van der Riel PL, van Leeuwen MA et ai, Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients, Br J Rheumatol 31, 519–525 (1992).
   PubMedGoogle Scholar
• Pincus T, Callahan F, Prognostic markers of activity and damage in rheumatoid arthritis: why clinical trials and inception cohort studies indicate were favourable outcomes than studies of patients with established disease (Editorial), Br J Rheumatol 34, 196–199 (1995).
   Google Scholar
• Combe B, Eliaow JF, Doures JP et al., Prognostic factors in rheumatoid arthritis: Comparative study of two subsets of patients according to severity of articular damage, Br J Rheumatol 34, 529–534 (1995).
   PubMedGoogle Scholar
• Hochberg MC, Predicting the prognosis of patients with rheumatoid arthritis: is there a crystal ball? (Editorial), J Rheumatol 20, 1265–1267 (1993).
   Google Scholar
• Kolarz G, Mayrhofer F, Peichl P et al. Prognostic factors for the outcome of methotrexate treatment in rheumatoid arthritis, Clin Rheumatol 14, 515–518 (1995).
   Google Scholar
• Coste J, Spira A, Clerc D, Paolaggi J, Prediction of articular destruction in rheumatoid arthritis: disease activity markers revisited, J Rheumatol 24, 28–34 (1997).
   PubMed Web of Science ®Google Scholar
• Wilske KR, Healey LA, Remodeling the pyramid: a concept whose time has come (Editorial), J Rheumatol 16, 565–567 (1989).
   PubMed Web of Science ®Google Scholar
• Weuamd CM, Hicok KC, Goronzy JJ et ai, The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis, Ann Intern Med 117, 801–806 (1992).
   Google Scholar
• Toda H, Maekawa T, Takemura S et al., The relationship between HLA-DRB1 genotype and progression of bone destruction with rheumatoid arthritis, Jpn J Rheumatol 6, 363–371 (1996).
   Google Scholar